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of folding-back and averaging-out were repeatedly applied until the expected values 
of beneﬁt and cost are eventually calculated at the ﬁrst decision-node. RESULTS: 
Comparing Teb to Tc, we obtained the incremental cost and beneﬁt for (p(1-B)  
A(1-p))(Ca – Cb) and p(1-B)(Ea – Eb), respectively. Then, dividing the former by the 
latter resulted in the formula: r-ICER  (1k) x ICER, where k  (A(1-p))/((1-B)p). It 
implies that the risk-adjustment corrects the underestimation of ICER since k takes a 
positive value. Hence, the efﬁciency frontier deﬁned by a series of r-ICERs transformed 
into an inferior position, compared to the original one. CONCLUSIONS: The r-ICER 
can correct an underestimate of the standard ICER and will be useful in risk-sensitive 
evaluation using ICERs including the efﬁciency frontier.
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TRADITIONAL OUTCOME MEASURES FOR USE IN HEALTH CARE 
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OBJECTIVES: Non-traditional outcomes (NTOs), those related with patient reported 
outcomes (PROs), economic and non-traditional clinical outcomes, are frequently 
being used to assess health interventions. We propose a standardized approach to 
assess the utility of NTO measures for use in health care decision making. METHODS: 
A systematic review of NTOs in Type 2 Diabetes Mellitus (T2DM) was conducted. 
Inclusion and exclusion criteria, data sources, search strategy, and data extraction and 
quality assessment of the studies and NTOs were deﬁned. The degree of recommenda-
tion of each NTOs was based on the quality of the outcome and the scientiﬁc evidence 
to support it. Two independent reviewers carried out each activity. RESULTS: NTOs’ 
were assessed within a three-grade quality scale in terms of feasibility, validity, sensi-
tivity, reliability, comparability and understanding. NTOs were categorized as key, 
important, and with not enough evidence to support its use in health decision-making. 
Case study in T2DM: 3805 citations and 235 potentially eligible full articles were 
retrieved and 153 studies met the inclusion criteria. Eighty-eight (5 clinical, 54 human-
istic and 29 economic) NTOs in T2DM were retrieved. A total of 21.6% of the NTOs 
were considered key, 36.4% important and for 42% not enough evidence was found 
to support its use in T2DM. CONCLUSIONS: An evidence based understanding of 
NTOs’ validity to measure treatment outcomes in different conditions is needed since 
clinicians and payers may use them for decision-making purposes.
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OBJECTIVES: Meta-analyses are recommended and frequently utilized in cost-effec- 
tiveness analyses. The aim of this study was to assess if efﬁcacy data obtained from              
one meta-analysis is used differently in various cost-effectiveness analyses of oral anti-
migraine medications (triptans). METHODS: A literature review was conducted in 
order to identify studies, assessing the cost-effectiveness of triptans, that used the 
meta-analysis by Ferrari et al. (2002) as the primary source of efﬁcacy. Studies were 
included in the literature review if they assessed the cost-effectiveness of two or more 
triptans (almotriptan, eletriptan, frovatriptan, naratriptan, sumatriptan, rizatriptan or 
zolmitriptan) in the adult population using an average or incremental cost-effectiveness 
ratio as an outcome measure. RESULTS: In total, 12 studies were included in the ﬁnal 
review. Five different measures of efﬁcacy were used in the reviewed studies. These 
were “sustained pain free with no adverse effects” (n  6), “24 hour sustained response” 
(n  3), “sustained pain free” (n  4), “pain free at two hours” (n  1), and “quality 
adjusted life year” (QALY) (n  2). In addition, four alternative methods were used 
to calculate the “sustained pain free with no adverse effects”. In total, this resulted in 
eight alternative measures of efﬁcacy derived from a single meta-analysis. CONCLU-
SIONS: The choice of efﬁcacy measure can differ between different cost-effectiveness 
studies, even those based on same literature source. This may affect the applicability 
of the cost-effectiveness analysis in decision making. However, the underlying reasons 
for the variation in the choice of efﬁcacy measure, and the association between choice 
of efﬁcacy measure and the study conclusion need thorough research. Therefore, there 
is still room for conventional one-way sensitivity analyses that enable evaluation of 
the effects of “qualitative” data source uncertainties on the study results.
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Recently, several checklists have been developed which systematically check the trans-
ferability of cost-effectiveness (CE) studies between jurisdictions. Some even provide 
a quantitative score of the degree of transferability. The interpretation of such a score 
is, however, difﬁcult. In addition, the threshold value for a QALY is a factor that has 
been given little consideration in these checklists. The importance of a factor as a 
cause of between-country differences in CE depends on this threshold: factors that 
explain most of the differences in CE at a low threshold need not be the same factors 
at a higher threshold. OBJECTIVES: To compare the impact of nine potential causes 
of variation in CE of smoking cessation support (SCS), at different thresholds for the 
willingness-to-pay per QALY (WTP). METHODS: A model-based study compared 
the cost-effectiveness of SCS between six Western-European countries. For several 
values of WTP, we investigated the impact of between-country differences in nine 
factors on the incremental net monetary beneﬁt (INMB). The factors were demogra-
phy, smoking prevalence, mortality, epidemiology and costs of smoking-related dis-
eases, resource use and unit costs of SCS, utility weights and discount rates. RESULTS: 
Currently, SCS is not reimbursed in The Netherlands, corresponding to a WTP of 
a 0. With a WTP below a1000, the factors most responsible for between-country dif-
ferences in INMB are resource use and unit costs of SCS and the costs of smoking-
related diseases. Utility values have little impact. At a threshold above a10,000, 
between-country differences are primarily due to different discount rates, utility 
weights and epidemiology of smoking-related diseases (incidence and mortality). Costs 
of smoking-related diseases have little impact above a20,000. At all thresholds, 
demography has little impact. CONCLUSIONS: When judging the transferability of 
a CE study to another jurisdiction, we should consider the between-country differences 
in threshold values per QALY.
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OBJECTIVES: Due to setting speciﬁc characteristics the economic attractiveness of 
new technologies might vary between hospitals. We compared classical and statistical 
process control (SPC) methods for measuring and monitoring the real-world cost-
effectiveness of new technologies in hospitals. METHODS: A systematic literature 
review was performed in PubMed in April 2009 to identify studies applying classical 
and SPC methods for investigating the (cost-)effectiveness of changes in inpatient       
health care processes. Both methodologies were compared using a predeﬁned set of cri-       
teria such as accuracy, ﬂexibility, informative value, suitability and user-friendliness. 
RESULTS: Classical statistical methods based on ‘time static’ (cross-sectional) statisti-
cal analysis with aggregated data are widely used. With the ability to detect statistical 
signiﬁcant differences classical methods may provide higher accuracy. They are char-
acterized by large one-time data collections to evaluate the impact of a process change 
for a pre-speciﬁed time period, limiting their ﬂexibility. SPC methods which analyze 
time series data by monitoring a process over time have been used rarely but their 
application is increasing. They combine time series analysis with a graphical represen-
tation of the data. Patterns in time series data contain important information which 
other methods reliant on averages (or other summary statistics) could mask. By provid-
ing continuous feedback SPC is capable not only of detecting the results of process 
changes earlier but also of monitoring the process sustainability. SPC can be applied 
to routine data easier as it is typically less sensitive to statistical issues. Furthermore, 
the graphical representation of the data has advantages because statistical measures 
such as P-values are often poorly understood and misinterpreted. CONCLUSIONS: 
Both methodologies are suitable for measuring the (cost)-effectiveness of changes in 
health care processes. SPC seems to be the preferred methodology under real-world 
conditions to support decision-making although it commonly does not achieve the 
accuracy of classical statistical methods.
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OBJECTIVES: Inadequate reporting of continuous outcomes is a major problem while 
performing meta-analysis. The objective of this study is to estimate the nature and 
scale of inadequate reporting of continuous outcomes. METHODS: Reporting quality 
of continuous outcomes (baseline, endpoint and change from baseline data) was ana-
lysed across four disease area reviews conducted in lipid disorder, overactive bladder, 
multiple sclerosis and rheumatoid arthritis. Reporting quality was considered inade-
quate when either number of patients analysed (N) was not reported or error term 
was missing/could not be calculated from the reported statistics. Analyses were con-
ducted using STATA 9.2. RESULTS: In total 12,236 reported outcomes across the 
four systematic reviews were included in the analysis. Inadequate reporting of continu-
ous outcomes was frequent and observed for 3912 (31.97%) outcomes. The estimate 
of inadequate reporting varied across selected reviews and ranged from 27.10% to 
45.77% in lipid disorder and overactive bladder, respectively. Of the outcomes 
reported inadequately, number of patients analysed (N) was missing for 8.82% 
whereas error term was missing or could not be calculated for 91.18% outcomes. 
When the reporting quality was analysed by the outcome type, it was observed that 
change from baseline data were often reported inadequately (49.63%) compared to 
baseline & endpoint data (25.00% and 24.51%, respectively). CONCLUSIONS: 
Inadequate reporting of continuous outcome was frequently observed among the 
selected reviews especially for the change from baseline outcomes. The results dem-
onstrated that for majority of the outcomes, the error term was either missing or could 
not be calculated from the given statistics. This inadequacy of reporting could have a 
signiﬁcant impact on the results of meta-analysis. Our results are indicative of outcome 
reporting bias which needs to be investigated further.
